Circulating receptor activator of nuclear factor kappa-B ligand (RANKL) levels predict response to immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC).
Michele IulianiSonia SimonettiLeonardo CristofaniSilvia CavaliereAlessio CortelliniMarco RussanoBruno VincenziGiuseppe ToniniDaniele SantiniFrancesco PantanoPublished in: Journal for immunotherapy of cancer (2024)
These results highlight the prognostic and predictive value of RANKL specifically in patients with high PDL1 expression.